Patents expiring in 2038

US 10046068

Saccharide conjugates

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10046028

Methods and compositions for modulating PD1

Sangamo Therapeutics, Inc. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10046036

Chemically modified cystathionine β-synthase enzyme for treatment of homocystinuria

The Regents of the University of Colorado, a Body Corporate · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10046057

Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy

The Regents of the University of California · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10047028

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

Esperion Therapeutics, Inc. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10047095

sGC stimulators

IRONWOOD PHARMACEUTICALS, INC. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10047104

Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

Aurigene Discovery Technologies Limited · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10047153

Human antibodies to Fel d1 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10047125

Peptide having activity to improve skin condition and use thereof

CAREGEN CO., LTD. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10047147

Neutralizing GP41 antibodies and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10047160

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

CA 3046406

PRODUIT DE REMPLACEMENT DE FACTEUR DE COAGULATION SANGUINE POUR UTILISATION DANS LE TRAITEMENT PROPHYLACTIQUE OU THERAPEUTIQUE DES HEMORRAGIES

CSL BEHRING GMBH [DE] · Granted Thu Aug 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Aug 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10052362

Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions

The United States Geovernment represented by the United States Department of Veterans Affairs · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10051880

Hydroxybutyrate ester and medical use thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10052349

Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

RegenLab USA LLC · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10053494

Chemically activated nanocapsid functionalized for cancer targeting

The Regents of the University of California · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10053689

Methods for increasing efficacy of lipid formulated siRNA

ARBUTUS BIOPHARMA CORPORATION · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10053706

Parental RNAi suppression of chromatin remodeling genes to control coleopteran pests

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10053514

Human bispecific EGFRvIII and CD3 antibody engaging molecules

The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10053417

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10052393

Multifunctional nanomaterials for the treatment of cancer

The Regents of the University of Colorado, a Body Corporate · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10052382

Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides

The United States of America as Represented by the Secretary of Health (NIH) · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10052363

Mesenchymal stem cells for the treatment of CNS diseases

BRAINSTORM CELL THERAPEUTICS LTD. · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10052386

Progesterone formulations

Compass Therapeutics LLC · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10052467

Applicator for applying a fluid to a surface

AMNEAL PHARMACEUTICALS LLC · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10053456

Cyclopropanamine compound and use thereof

Takeda Pharmaceutical Company Limited · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10053468

Heterocyclic compound

Takeda Pharmaceutical Company Limited · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10053469

Pyridone and aza-pyridone compounds and methods of use

GILEAD CONNECTICUT, INC. · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10053503

Monoclonal antibodies that neutralize anthrax toxins

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10052374

Compositions, methods and uses for dengue virus serotype-4 constructs

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10052371

Compositions and methods for treatment of cancer using bacteria

Decoy Biosystems, Inc. · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10052369

Aquaporin 2 protects cattle from ticks and tick-borne parasites

The United States of America, as represented by the Secretary of Agriculture · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10060921

Methods of treating transthyretin (TTR) mediated amyloidosis

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058559

Treatment or prevention of an intestinal disease or disorder

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10059744

α4β7 thioether peptide dimer antagonists

Protagonist Therapeutics, Inc. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10059762

Anti-EGFR activatable antibodies

CytomX Therapeutics, Inc. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058521

Omega-3 pentaenoic acid compositions and methods of use

MATINAS BIOPHARMA INC. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058614

Pharmaceutical compositions comprising meloxicam

AXSOME THERAPEUTICS, INC. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10059771

Methods for treating nasal polyposis by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058587

Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity

Soricimed Biopharma Inc. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10059689

Substituted heteroaryl compounds and methods of use

SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058554

Sustained release small molecule drug formulation

Indivior UK Limited · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058557

Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

ESSENTIALIS, INC. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058561

Methods and related compositions for reduction of fat and skin tightening

The Regents of the University of California · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058572

Placenta-derived multipotent stem cells

The Regents of the University of California · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058556

Method of treatment of aggression

Supernus Pharmaceuticals, Inc. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058546

Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10058593

Methods and compositions for oral administration of proteins

Oramed Ltd. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)